These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 6667681)

  • 1. Treatment of gram-negative bacillary septicemia with cefoperazone.
    Lagast H; Meunier-Carpentier F; Klastersky J
    Eur J Clin Microbiol; 1983 Dec; 2(6):554-8. PubMed ID: 6667681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cefoperazone for the treatment of infections in patients with cancer.
    Bolivar R; Fainstein V; Elting L; Bodey GP
    Rev Infect Dis; 1983; 5 Suppl 1():S181-7. PubMed ID: 6221389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cefoperazone: an analysis of results in the pediatric population from a post-marketing surveillance study in hospitalized patients. The Cefoperazone Collaborative Post-marketing Surveillance Study Group.
    Indian J Pediatr; 1998; 65(1):89-98. PubMed ID: 10771951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical experience with the treatment of severe nosocomial infections by inhibitor-protected 3rd generation cephalosporin cefoperazone/sulbactam].
    Beloborodova NV; Kuznetsova ST; Popov DA; Bachinskaia EN; Vostrikov TIu
    Antibiot Khimioter; 2005; 50(4):33-40. PubMed ID: 16392338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-drug versus combination empirical therapy for gram-negative bacillary infections in febrile cancer patients with and without granulocytopenia.
    Piccart M; Klastersky J; Meunier F; Lagast H; Van Laethem Y; Weerts D
    Antimicrob Agents Chemother; 1984 Dec; 26(6):870-5. PubMed ID: 6524903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cefoperazone for infections in cancer patients.
    Bodey P; Rolston K; Hsi Ho D
    Chemioterapia; 1987 Jun; 6(2 Suppl):400-2. PubMed ID: 3509458
    [No Abstract]   [Full Text] [Related]  

  • 7. Multicenter clinical trials of cefoperazone in Japan.
    Saito A; Ueda Y
    Clin Ther; 1984; 7(1):49-59. PubMed ID: 6394129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cefoperazone versus ceftazidime monotherapy of nosocomial pneumonia.
    Mangi RJ; Ryan J; Berenson C; Greco T; Simms M; Thornton G; Andriole VT
    Am J Med; 1988 Jul; 85(1A):44-8. PubMed ID: 3041818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter clinical trial of cefoperazone sodium in the United States.
    Cohen MS; Washton HE; Barranco SF
    Am J Med; 1984 Jul; 77(1B):35-41. PubMed ID: 6380285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical trials with cefoperazone in the field of internal medicine in Japan.
    Mashimo K; Kunii O
    Clin Ther; 1980; 3(Spec Issue):159-72. PubMed ID: 6446392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cefoperazone--Possibility of safer treatment for infections in patients with chronic renal failure].
    Klinger M; Szewczyk Z; Kazimierczak K; Kramarz S
    Wiad Lek; 1990 Aug 1-15; 43(15-16):773-6. PubMed ID: 2275197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cefoperazone-sulbactam for treatment of intra-abdominal infections: results from a randomized, parallel group study in India.
    Chandra A; Dhar P; Dharap S; Goel A; Gupta R; Hardikar JV; Kapoor VK; Mathur AK; Modi P; Narwaria M; Ramesh MK; Ramesh H; Sastry RA; Shah S; Virk S; Sudheer OV; Sreevathsa MR; Varshney S; Kochhar P; Somasundaram S; Desai C; Schou M
    Surg Infect (Larchmt); 2008 Jun; 9(3):367-76. PubMed ID: 18570578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of protein binding on therapeutic efficacy of cefoperazone.
    Peterson LR; Moody JA; Fasching CE; Gerding DN
    Antimicrob Agents Chemother; 1989 Apr; 33(4):566-8. PubMed ID: 2729948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of cefoperazone in the treatment of bacterial infections in patients with hematological diseases.
    Ichimaru M; Takatsuki K; Niho Y; Sawae Y
    Clin Ther; 1984; 7(1):60-8. PubMed ID: 6518464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial activity, pharmacokinetics, adverse reactions, and therapeutic indications of cefoperazone.
    Funk EA; Strausbaugh LJ
    Pharmacotherapy; 1982; 2(4):185-96. PubMed ID: 6221236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter clinical study of cefoperazone.
    Alix M; Arreza V; Brillantes S; Estrellado R; Gempesaw C; Monteron R; Pascasio F; Pena A; Claudio-Saniel M
    Clin Ther; 1984; 6(3):344-53. PubMed ID: 6722861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single agent therapy for infections in cancer patients: a prospective randomized trial comparing three extended-spectrum cephalosporins.
    Rolston KV; Jones PG; Fainstein V; Khardori NM; Anaissie EJ; Steelhammer L; Bodey GP
    Eur J Clin Microbiol Infect Dis; 1991 Mar; 10(3):139-45. PubMed ID: 2060514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, controlled trial of cefoperazone vs. cefamandole-tobramycin in the treatment of putative, severe infections with gram-negative bacilli.
    Warren JW; Miller EH; Fitzpatrick B; DiFranco DE; Caplan ES; Tenney JH; Anthony WC
    Rev Infect Dis; 1983; 5 Suppl 1():S173-80. PubMed ID: 6221388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An open trial of cefoperazone plus sulbactam for the treatment of fever in cancer patients.
    Bodey GP; Elting LS; Narro J; Koller C; O'Brien S; Estey E; Benjamin R
    J Antimicrob Chemother; 1993 Jul; 32(1):141-52. PubMed ID: 8226405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cefoperazone compared with ampicillin plus tobramycin for severe biliary tract infections.
    Bergeron MG; Mendelson J; Harding GK; Mandell L; Fong IW; Rachlis A; Chan R; Biron S; Feld R; Segal NB
    Antimicrob Agents Chemother; 1988 Aug; 32(8):1231-6. PubMed ID: 3056255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.